NOX CEO Interview on Orphan Drug Status

  1. 392 Posts.
    lightbulb Created with Sketch. 132
    Our new CEO Gisela Mautener has just given a great interview on the Proactive channel mainly regarding the newly announced FDA  award of Orphan Drug Status to Noxopharm. It’s only 8 minutes long but packs in quite a bit of detail.

    Well worth a listen.

    **promotion blocked**.au/companies/...phan-drug-designation-from-us-fda-977803.html

    The future is brightening up after the recent malaise across a number of smaller biotechs. Here’s hoping we get more good news in the near future.

    Apples
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.4¢
Change
-0.006(6.00%)
Mkt cap ! $27.47M
Open High Low Value Volume
10.0¢ 10.0¢ 9.4¢ $694 7.068K

Buyers (Bids)

No. Vol. Price($)
1 35392 9.4¢
 

Sellers (Offers)

Price($) Vol. No.
10.0¢ 75537 1
View Market Depth
Last trade - 15.59pm 09/09/2025 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.